Overview

A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To test the effectiveness of recombinant human CD4 Immunoglobulin G (CD4-IgG) in the treatment of HIV-associated immune thrombocytopenic purpura in patients with all levels of HIV infection.

Phase:

Phase 1

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Antibodies
CD4 Immunoadhesins
Immunoglobulin G
Immunoglobulins